Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Georgetown University
Bristol-Myers Squibb
Incyte Corporation
Mayo Clinic
UCB Pharma
Imugene Limited
ImmunityBio, Inc.
ImmunityBio, Inc.
Immodulon Therapeutics Ltd
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
Academic and Community Cancer Research United
Ludwig Institute for Cancer Research
SWOG Cancer Research Network
Sumitomo Pharma America, Inc.
Eisai Inc.
MedImmune LLC
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
Incyte Corporation
University of Louisville
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Brown University
Symphogen A/S
Northwestern University
Eli Lilly and Company
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
NYU Langone Health
City of Hope Medical Center
Massachusetts General Hospital
Massachusetts General Hospital
University of Utah
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Merck KGaA, Darmstadt, Germany
AstraZeneca
Case Comprehensive Cancer Center